CAVA heads into the post-earnings week with shorts pulling back sharply, analysts resetting targets lower, and the stock trading at a valuation that still leaves little room for error.
The most striking move this week was the rapid unwinding of short positions. Short interest fell nearly 15% over the week to 10.9% of the free float — down from a peak near 14.9 million shares at the end of July. Tuesday's single-session drop of 12% in short shares was the steepest move in the series. The retreat is notable, but 10.9% of float remains elevated in absolute terms, and borrowing costs have been quietly rising — up 27% over the week to 0.56%. That combination suggests covering, not a change in conviction. Availability is generous at roughly 389% of short interest, meaning there is ample room for fresh shorts to rebuild if the thesis reasserts.
Options positioning is lean on bearishness. The put/call ratio came in at 0.77, a touch below its 20-day average of 0.80 and well off the defensive readings near 0.88 that were in place through late July. The z-score is negligibly negative, implying options traders are neither pressing bearish bets nor loading up on upside calls. That reads less as conviction and more as a market waiting to see what the next data point brings — which, with a confirmed earnings date of September 1, is not far away.
The analyst response to Tuesday's print has been mixed in direction but uniformly lower on targets. Most of the Street held its ratings — bulls at Roth Capital, KeyBanc, RBC, and TD Cowen stayed constructive — but all trimmed targets into the $85–$95 range from prior levels in the $100–$110 band. Mizuho, which holds a Neutral, was the most aggressive cutter, dropping its target to $70 from $85. The exception was Wolfe Research, which nudged its Outperform target up to $82 from $79, and RBC — which raised its target to $95 after having cut to $90 just six days earlier. The mean target of $89 implies around 46% upside from current levels at $60.81, though that gap looks less compelling when the PE has already compressed 20 points over the past month to around 90x and the EV/EBITDA has drifted down toward 32x. Factor scores add nuance: analyst recommendation divergence ranks in the 94th percentile, reflecting genuine disagreement, while the EV/EBIT score sits in the 4th percentile — a signal that the valuation story remains a sticking point for value-oriented investors.
The institutional picture shows incremental buying rather than large-scale repositioning. AllianceBernstein added 1.7 million shares in the most recent reported period, making it the most active of the top holders. Capital Research, BlackRock, Fidelity, and T. Rowe Price are all running modestly positive net changes. On the insider side, the noteworthy cluster from mid-June — when a 10% board-represented owner sold 3 million shares at $90.30 alongside CEO Brett Schulman and CFO Tricia Tolivar — now looks prescient given the subsequent 32% decline in the share price. Insider data runs only through June 18, so the next filing window will be worth watching for any change in tone from management.
The closest peer group tells a divergent story this week. BROS fell 22.7% on the week — sharper than CAVA's 4.1% drop — while SG and CMG each slid around 5%. SHAK, by contrast, gained 8.4%, suggesting the pain is concentrated in growth-priced restaurant names rather than the sector broadly. With the ORTEX short score easing from 62 to 57 over the past two weeks as shorts cover, the focus now shifts to whether September 1 earnings can reverse the negative momentum on same-store sales that the bear case has been building around.
See the live data behind this article on ORTEX.
Open CAVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
